Case Report: Macula Structural and Functional Assessment in Nab-Paclitaxel–Related Cystoid Macular Edema

Abstract

Nab-paclitaxel–related cystoid macular edema is a rare ophthalmic adverse drug reaction. We present a 54-year-old woman with metastatic hormone receptor positive, HER-2 negative breast carcinoma who developed profound bilateral vision loss after the seventh cycle of nab-paclitaxel treatment. Optical coherence tomography and macula microperimetry demonstrated macular edema and decreased threshold sensitivity, respectively. Cessation of nab-paclitaxel improved structural and functional vision after 4 weeks. The introduction of topical dorzolamide 1% in one eye demonstrated further rapid resolution of edema. We demonstrate the objective and subjective visual changes and recovery of nab-paclitaxel–related cystoid macular edema. [ Ophthalmic Surg Lasers Imaging Retina 2024;55:408–411.]